In Part 2 of the study, subjects will be randomized to receive either INCB039110 or placebo and docetaxel. The dose and frequency of INCB039110 and docetaxel administered will be determined from Part 1 of the study. INCB039110/placebo will be self-administered each day during the entire cycle. This part of the study will be conducted in a double-blind, randomized manner.